ATI-1123: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 29 patients with solid tumors showed that 15-110 mg/m 2 IV ATI-1123 given every 3 weeks produced 22 cases of stable disease and 1 partial response...